BridgeBio Pharma (BBIO) Debt Ratio (2018 - 2026)

BridgeBio Pharma has reported Debt Ratio for 9 years, with the latest figure at 2.33 in Q1 2026.

• Quarterly Debt Ratio changed N/A year-over-year to 2.33 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.33 (changed N/A YoY) and the FY2025 annual result came in at 0.79, up 66.39% from the prior year.
• Debt Ratio grew to 2.33 in Q1 2026 per BBIO's latest filing, from 0.79 in the prior quarter.
• Over five years, Debt Ratio peaked at 2.33 in Q1 2026 and troughed at 0.48 in Q4 2024.
• A 5-year average of 0.85 and a median of 0.67 in 2023 frame the typical range for Debt Ratio.
• The sharpest annual moves came in 2022 and 2024: Debt Ratio surged 518.25% in 2022, then plunged 41.78% in 2024.
• Over 5 years, Debt Ratio stood at 0.69 in 2022, then increased by 18.12% to 0.82 in 2023, then slumped by 41.78% to 0.48 in 2024, then jumped by 66.39% to 0.79 in 2025, then soared by 194.92% to 2.33 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 2.33, 0.79, and 2.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.